This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veterinary Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Development
Chimeric Antigen Receptor T-cell therapy is a common and important cellular immunotherapy that targets and eliminates tumor cells by modifying immune cells and enhancing immune responses. This innovative therapy has demonstrated success in human studies for the treatment of tumors found in the blood, bone marrow or lymph nodes, such as leukemia and lymphoma. BioVenic is extending the advanced technology of CAR-T therapy to the treatment of companion animal diseases, providing veterinary CAR-T therapy related technologies to researchers. Our team of specialists has well-established technical procedures and extensive project expertise in animal cell modification, making us highly capable of T cell-related engineering modifications in the development phase of cell therapy.
Background
In recent years, CAR T-cell therapy in veterinary medicine has developed and matured at an unprecedented rate, marking a new stage in the development of treatment options for animals. CAR T cells have undergone several generations of improvement and optimization, continuously improving safety, survival and functionality. In the treatment of cancer in companion animals, CAR-T cell therapy has attracted considerable attention, and its optimization methods, principle clarification, and standardized generation system have become research hotspots for scientists worldwide.
Fig.1 Adoptive cell immunotherapy possibilities for cancer in dogs.1,2
Veterinary CAR-T Therapy Development Services
BioVenic specializes in researching promising CAR-T immune cell therapy development for veterinary use. We are dedicated to achieving targeted improvements in CAR transduction, T cell survival, proliferation, and engraftment. We excel in various biotechnologies related to animal cell transfection and in vitro culture. Our dedicated team skillfully inserts CAR sequences into the T cell genome, enabling T cells to specifically recognize and bind to tumor cells in diseased animals, ultimately leading to their destruction.
- CAR Design
A sound overall design of chimeric antigen receptors (CARs) is a key strategy to effectively enhance the therapeutic potential of CAR T cells. BioVenic focuses on optimizing the four components of the CAR structure: extracellular domain, hinge, transmembrane domain, and intracellular signaling domain to achieve the most appropriate molecular design tailored to specific functions. At the same time, our expert team masters the process of costimulating and activating immune cells to achieve proliferation, differentiation and survival. This ensures that veterinary CAR-T cells function optimally. The CAR-T is optimized by combining it with appropriate costimulatory molecules to overcome the inhibitory environment created by tumor cells in sick animals.
- CAR-T Cell Preparation
BioVenic supports customers in tailoring T cell preparation solutions for veterinary CAR T cell therapy. We help customers address a range of scientific research challenges, from T cell collection and culture to activation and CAR transduction. Leveraging our extensive experience in primary animal cell isolation, in vitro culture projects, and advanced cell biology technology platforms, we provide reliable T cell isolation and preparation services to researchers worldwide.
- Targeting Multiple Antigens Exploration
BioVenic has been working for many years to overcome the various limitations of veterinary CAR-T cell therapy, in particular the resistance of tumor cells to single antigen CAR constructs. We are helping to address these issues through a variety of strategies, including the construction and use of dual CAR constructs, or tandem CARs. Tandem CARs are single CAR constructs containing two scFvs targeting multiple tumor antigens simultaneously. By inducing different levels of transformation in T cells, their targeting efficacy is enhanced, antigen escape is minimized, and the therapeutic value and potential of the overall therapy is increased.
Technology and Process
| From T Cells to CAR-T Cells |
Autologous CAR-T cell therapy Because CAR T cells are harvested from the diseased animal itself, they can be stored in the body for an extended period of time, and the therapeutic effect depends primarily on the quantity and quality of the autologous cells. |
1. Collect T cells from animals via leukapheresis 2. Match the collected T cells with an appropriate culture environment and optimal culture conditions. 3. Activate T cells with appropriate stimulation, including antibodies and artificial antigen-presenting cells. 4. Insert the CAR gene into T cells using viral vectors or non-viral methods to achieve CAR transduction. 5. After transduction, the cells are cultured for 7-14 days to expand and express the selected CAR-T structure. CAR T cells that meet the release criteria are then cryopreserved. |
Potential applications:
|
|
Allogeneic CAR-T cell therapy The collection of T cells from healthy animals of the same species allows the simultaneous mass production and storage of CAR T cells. These cells have a relatively short lifespan in the body and face the risk of allogeneic immunity. |
Why Choose Us?
BioVenic's professional technical platform and operational specifications ensure the sterility, safety and efficacy of veterinary CAR-T cell development.
BioVenic has been engaged in the field of animal cytology for many years and has accumulated rich experience in basic operations such as isolation and culture of primary cells.
BioVenic has established a comprehensive service system and a specialized experimental team for the development of veterinary cell therapy to fully meet personalized requirements in CAR-T development.
BioVenic offers a full range of customized solutions for researchers developing veterinary CAR-T therapies with a focus on improving T cell survival, proliferation and functionality. We excel in various biotechnologies related to animal cell transfection, in vitro survival and maintenance. Our expertise allows us to seamlessly integrate CAR sequences into animal T cell genomes, enabling them to specifically target and bind to tumor cells and ultimately destroy them by releasing factors such as perforin. We stand ready to be your competent scientific partner in advancing the promising veterinary CAR-T therapies. If you are facing challenges in this area of research, please contact us.
References
- Image retrieved from Figure 3 " Adoptive cell immunotherapy possibilities for cancer in dogs include transfer of TILs, TRC-modified and CAR-engineered T lymphocytes." Bujak et al., 2018, used under [CC BY 4.0] (https://creativecommons.org/licenses/by/4.0/). The original title was changed to "Adoptive cell immunotherapy possibilities for cancer in dogs."
- Bujak, Joanna Katarzyna, et al. "Adoptive cell transfer: new perspective treatment in veterinary oncology." Acta Veterinaria Scandinavica 60 (2018): 1-13.